A tau PET scan shows the estimated density and location of tau tangles, clumps of tau protein, in the brain. In an Alzheimer's evaluation, it helps doctors assess adults with cognitive impairment for Alzheimer's-related tau buildup. According to the FDA approval notice, the scan maps aggregated tau neurofibrillary tangles in adults being evaluated for Alzheimer's disease. Doctors read it alongside memory testing, exams, and other biomarkers.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How is the scan performed?
- What does a positive result look like?
- What does tau burden say about prognosis?
- What are the limits and next steps?
How is the scan performed?
The approved tracer is flortaucipir F18, sold as Tauvid. According to the DailyMed drug label from the National Library of Medicine, it is given as an intravenous bolus of about 370 MBq, with PET imaging starting about 80 minutes later.
The PET camera detects where the tracer has collected. Bright areas signal higher tau density in that brain region.
- Intravenous bolus of flortaucipir F18
- Wait period of about 80 minutes
- PET scan to image tau pathology
What does a positive result look like?
A positive scan shows rising tracer uptake that spreads in a known pattern. Early buildup often starts in medial and entorhinal areas of the temporal lobe. Later spread reaches lateral temporal, parietal, occipital, precuneus and posterior cingulate, and frontal regions.
That spread matters because location tracks disease stage. A scan confined to inner temporal areas looks different from widespread uptake across posterior and frontal cortex. The radiologist describes both intensity and distribution, not only positive or negative.
What does tau burden say about prognosis?
Greater tau burden and a higher Braak-like stage predict faster cognitive decline. Tau patterns also track thinking and memory severity more closely than amyloid plaques do.
So two people with similar amyloid results can have different outlooks when tau differs. Under revised criteria described by the Alzheimer's Association workgroup, tau PET is a Core 2 biomarker. It helps stage disease, estimate prognosis, and raise confidence that Alzheimer's is contributing to symptoms.
What are the limits and next steps?
Tau PET also helps separate Alzheimer's from some other brain disorders. Typical amnestic Alzheimer's often shows posterior temporal and parietal uptake.
Other neurodegenerative disorders tend to show different patterns or little tau uptake. A negative Tauvid scan alone does not rule out Alzheimer's and needs further evaluation. The drug is also not indicated for chronic traumatic encephalopathy and can show off-target binding.





